GenXys Health Care Systems, Inc., the global leader in precision prescribing software with embedded pharmacogenetic data, recently finalized another customer deal to advance precision medicine initiatives with Ohio-based Flexsus, the laboratory division of FlexHealth.
Combined with GenXys’ best-in-class precision prescribing platform, Flexsus can now perform pharmacogenomic (PGx) testing and report results that identify medication that may be most efficacious for individuals based upon their genomic profile, with the goal of enhancing patient wellness. Flexsus also performs molecular testing that aids in the diagnosis or detection of pathogens, measures the progress or recovery from infection, or confirms that an individual is free from infection.
Recommended AI News: How Startups are Leveraging the Cloud to Scale
GenXys’ award-winning precision prescribing software with embedded pharmacogenetics will ensure differentiated PGx solutions for the Flexsus networked pharmacists and expanded medication review capabilities with PGx inclusion to drive PGx use. GenXys will overlay its expertise with the delivery of a seamless connection and securitized data flow between Laboratory Information Management Systems, electronic health records, and other systems. It will also include patient health variables and interactions beyond PGx to provide absolute confidence in prescribing decisions.
GenXys is helping to make marked changes in the way people approach precision medicine in community care.
“As North America’s powerhouse support tool for precision prescribing, we are proud of the number of PGx profiles our software processes,” says Karl Pringle, CEO of GenXys. “Being a cloud-based solution means all our customers are conforming to the latest clinical and pharmacogenetic guidelines set by CPIC, FDA, and other industry groups. Providing evidence-based prescribing support with real-time PGx assessment and inclusion is becoming a must-have, not a nice-to-have. Through the integration with Flexsus, we’re also able to include existing medication history into the clinical decision support process and enable providers to use PGx data automatically at the point of care.”
Recommended AI News: Nintex Named a Leader in Workflow and Content Automation by Aragon Research
GenXys is continuing the trend to land high-quality partners and build a substantial user base covering thousands of patients.
“The GenXys software suite will allow Flexsus to offer unparalleled services to its customers and improve patient safety and treatment response,” said Samuel Tang, CEO of Flexsus. “The flexibility of the GenXys platform coupled with the company’s unwavering focus on established evidence made them a clear fit for our providers and patients who want the ultimate confidence in the prescribing decisions.”
GenXys also continues to expand its U.S.-focused delivery team of professionals with the recent addition of David Wolfe, an established leader at the intersection of pharmacogenomics, clinical care, pharmacy informatics, and hospital pharmacy computer systems.
Recommended AI News: proteanTecs Secures $45 Million Investment from Addition
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.